NOVO NORDISK A/S

NYSE: NVO (Novo Nordisk A/S)

最近更新时间: 25 Nov, 8:17PM

47.06

2.09 (4.65%)

  • 1天 4.65%
  • 5天 -6.22%
  • 1月 -1.20%
  • 6月 -32.50%
  • 今年至今天 -46.23%
  • 1年 -46.95%
  • 5年 30.90%
前收盘价格 44.97
收盘价格 45.98
成交量 30,448,243
平均成交量 (3个月) 16,098,220
市值 209,110,155,264
市盈率 (P/E TTM) 12.52
预期市盈率 (P/E Forward) 13.00
价格/销量 (P/S) 4.27
股市价格/股市净资产 (P/B) 7.92
52周波幅
43.08 (-8%) — 112.52 (139%)
利润日期 4 Feb 2026
股息率 (DY TTM) 2.34%
营业毛利率 34.51%
营业利益率 (TTM) 49.68%
稀释每股收益 (EPS TTM) 3.67
季度收入增长率 (YOY) 19.50%
季度盈利增长率 (YOY) 14.30%
总债务/股东权益 (D/E MRQ) 85.70%
流动比率 (MRQ) 0.740
营业现金流 (OCF TTM) 131.24 B
杠杆自由现金流 (LFCF TTM) 77.73 B
资产报酬率 (ROA TTM) 23.29%
股东权益报酬率 (ROE TTM) 88.12%

市场趋势

短期 中期
行业 Drug Manufacturers - General (US) 混合的 看跌
Drug Manufacturers - General (全球的) 混合的 看跌
股票 Novo Nordisk A/S 看跌 看跌

AIStockmoo 评分

1.8
分析师共识 -0.5
内部交易活动 NA
价格波动 4.5
技术平均移动指标 1.0
技术振荡指标 2.0
平均 1.75

相关股票

股票 市值 DY P/E（TTM） P/B
NVO 209 B 2.34% 12.52 7.92
NVS 261 B 3.27% 18.61 5.67
LLY 960 B 0.14% 52.62 39.66
JNJ 497 B 0.60% 19.92 6.33
ABBV 394 B 1.47% 170.09 50.46
MRK 248 B 1.63% 13.12 4.80

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
部门 Healthcare
行业 Drug Manufacturers - General
投资方式 Large Core
内部持股比例 0.01%
机构持股比例 9.85%

所有权

姓名 日期 持有股份
Everett Harris & Co /Ca/ 30 Sep 2025 6,393,780
52周波幅
43.08 (-8%) — 112.52 (139%)
目标价格波幅
46.00 (-2%) — 70.00 (48%)
高 70.00 (HSBC, 48.75%) 购买
中 50.50 (7.31%)
低 46.00 (BMO Capital, -2.25%) 保留
平均值 54.25 (15.28%)
总计 2 购买, 1 保留, 1 卖出
平均价格@调整类型 52.66
公司 日期 目标价格 调整类型 价格@调整类型
Goldman Sachs 28 Nov 2025 54.00 (14.75%) 购买 49.35
BMO Capital 25 Nov 2025 46.00 (-2.25%) 保留 47.06
14 Oct 2025 55.00 (16.87%) 保留 56.66
HSBC 02 Oct 2025 70.00 (48.75%) 购买 58.74
Morgan Stanley 29 Sep 2025 47.00 (-0.13%) 卖出 55.50

该时间范围内无数据。

  • 3M
日期 类型 细节
19 Dec 2025 CNBC Wall Street banked on a flurry of deals under Trump in 2025. It wasn't that simple
12 Dec 2025 公告 Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss
11 Dec 2025 CNBC Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial  
09 Dec 2025 公告 Novo Nordisk has completed its acquisition of Akero Therapeutics
01 Dec 2025 CNBC Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
25 Nov 2025 公告 Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes
24 Nov 2025 CNBC Eli Lilly hits $1 trillion market value, a first in health care, as Novo Nordisk tumbles
24 Nov 2025 公告 Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression
17 Nov 2025 CNBC Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month
17 Nov 2025 公告 Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
14 Nov 2025 公告 Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S
13 Nov 2025 公告 Novo Nordisk A/S: Candidate for the Board of Directors will not seek election
11 Nov 2025 公告 Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
08 Nov 2025 公告 Novo Nordisk will not increase its proposal to acquire Metsera, Inc. 
07 Nov 2025 CNBC Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk
07 Nov 2025 CNBC Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk
06 Nov 2025 公告 Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
06 Nov 2025 公告 Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost
06 Nov 2025 CNBC Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
06 Nov 2025 CNBC Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study 
05 Nov 2025 公告 Novo Nordisk Wegovy® users achieved waist and BMI targets linked to improved health and low risk of obesity-related complications
05 Nov 2025 公告 Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues
04 Nov 2025 CNBC Metsera says Novo Nordisk’s new up to $10 billion bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
04 Nov 2025 CNBC Pfizer tops estimates, raises profit guidance even as sales fall
04 Nov 2025 公告 /C O R R E C T I O N -- Metsera, Inc./
04 Nov 2025 公告 Novo Nordisk submits updated proposal to acquire Metsera, Inc.
03 Nov 2025 CNBC Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
02 Nov 2025 CNBC Where the blockbuster weight loss drug market stands today — and what’s coming next
30 Oct 2025 CNBC Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar
30 Oct 2025 公告 Novo Nordisk submits proposal to acquire Metsera, Inc.
30 Oct 2025 公告 Metsera Receives Unsolicited Proposal from Novo Nordisk
29 Oct 2025 CNBC Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound
21 Oct 2025 公告 Notice convening an Extraordinary General Meeting of Novo Nordisk A/S
21 Oct 2025 公告 Novo Nordisk announces an Extraordinary General Meeting to be convened to elect new members of the Board of Directors
17 Oct 2025 CNBC Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s
15 Oct 2025 公告 Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)
09 Oct 2025 公告 Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio
30 Sep 2025 公告 SueWallSt Podcast Series Launches With Focus on Novo Nordisk A/S (NVO) Fraud Allegations
29 Sep 2025 公告 Novo Nordisk A/S (NVO) Shareholders Get Answers in Latest SueWallSt Podcast
23 Sep 2025 CNBC Eli Lilly to build $6.5 billion Texas manufacturing facility for obesity pill, other drugs
22 Sep 2025 CNBC Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera
显示更多
股息率 (DY TTM) 2.34%
5年平均股息收益率 2.48%
股息支付比率 47.09%
预计下次股息支付 Apr 2026
除息日 公告日期 支付日期 详情
31 Mar 2025 05 Feb 2025 08 Apr 2025 1.099206 现金
16 Aug 2024 06 Aug 2024 26 Aug 2024 0.5126402 现金
22 Mar 2024 31 Jan 2024 02 Apr 2024 0.92985 现金
18 Aug 2023 10 Aug 2023 29 Aug 2023 0.8835613 现金
24 Mar 2023 02 Feb 2023 04 Apr 2023 1.1887415 现金
12 Aug 2022 04 Aug 2022 23 Aug 2022 0.5835507 现金
25 Mar 2022 02 Mar 2022 05 Apr 2022 1.022423 现金
16 Aug 2021 - 25 Aug 2021 0.5502889 现金
26 Mar 2021 - 07 Apr 2021 0.922122 现金
14 Aug 2020 06 Aug 2020 25 Aug 2020 0.5177774 现金
27 Mar 2020 06 Feb 2020 07 Apr 2020 0.7826048 现金
16 Aug 2019 10 Aug 2019 27 Aug 2019 0.449438 现金
22 Mar 2019 05 Feb 2019 02 Apr 2019 0.777006 现金
17 Aug 2018 09 Aug 2018 28 Aug 2018 0.462327 现金
23 Mar 2018 24 Mar 2018 03 Apr 2018 0.805982 现金
17 Aug 2017 - 29 Aug 2017 0.33589 现金
23 Mar 2017 - 04 Apr 2017 0.479369 现金
11 Aug 2016 - 23 Aug 2016 0.331026 现金
18 Mar 2016 - 30 Mar 2016 0.69943 现金
19 Mar 2015 - 31 Mar 2015 0.532885 现金
21 Mar 2014 - 02 Apr 2014 0.606122 现金
21 Mar 2013 - 02 Apr 2013 2.264307 现金
22 Mar 2012 - 03 Apr 2012 1.831902 现金
24 Mar 2011 - 05 Apr 2011 1.357901 现金
25 Mar 2010 - 07 Apr 2010 0.978615 现金
19 Mar 2009 - 31 Mar 2009 0.781532 现金
13 Mar 2008 - 25 Mar 2008 0.678462 现金
08 Mar 2007 - 20 Mar 2007 0.891779 现金
09 Mar 2006 - 21 Mar 2006 0.691753 现金
10 Mar 2005 - 22 Mar 2005 0.61725 现金
17 Mar 2004 - 29 Mar 2004 0.52096 现金
26 Mar 2003 - 07 Apr 2003 0.37647 现金
13 Mar 2002 - 25 Mar 2002 0.2848 现金
21 Mar 2001 - 02 Apr 2001 0.5681 现金
24 Mar 2000 - 06 Apr 2000 0.4672 现金
25 Mar 1999 - 06 Apr 1999 0.4182 现金
27 Mar 1998 - 08 Apr 1998 0.3051 现金
25 Apr 1997 - 07 May 1997 0.239 现金
01 May 1996 - 14 May 1996 0.1806 现金
显示更多

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2025 1.10 1 2.34
2024 1.44 2 1.68
2023 2.07 2 2.00
2022 1.61 2 2.37
2021 1.47 2 2.63
2020 1.30 2 3.72
2019 1.23 2 4.24
2018 1.27 2 5.51
2017 0.815 2 3.04
2016 1.03 2 5.75
2015 0.533 1 1.84
2014 0.606 1 2.86
2013 2.26 1 12.26
2012 1.83 1 11.22
2011 1.36 1 11.78
2010 0.979 1 8.69
2009 0.782 1 12.24
2008 0.678 1 13.20
2007 0.892 1 13.75
2006 0.692 1 16.54
2005 0.617 1 21.94
2004 0.521 1 19.20
2003 0.376 1 18.38
2002 0.285 1 19.71
2001 0.568 1 28.33
2000 0.467 1 26.40
1999 0.418 1 32.36
1998 0.305 1 22.94
1997 0.239 1 16.57
1996 0.181 1 19.32
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明：以上内容仅供参考，并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票